Bicycle Therapeutics Ltd


Prices are adjusted according to historical splits.

Bicycle Therapeutics Ltd Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$676.90 million
Book Value:
Revenue TTM:
$14.46 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Bicycle Therapeutics Ltd had its IPO on 2019-05-23 under the ticker symbol BCYC.

The company operates in the Healthcare sector and Biotechnology industry. Bicycle Therapeutics Ltd has a staff strength of 236 employees.

Stock update

Shares of Bicycle Therapeutics Ltd opened at $21.87 at the start of the last trading session i.e. 2023-03-31.

The stocks traded within a range of $21.02 - $22.12, and closed at $21.27.

This is a -2.3% slip from the previous day's closing price.

A total volume of 130,770 shares were traded at the close of the day’s session.

In the last one week, shares of Bicycle Therapeutics Ltd have increased by +4.52%.

Bicycle Therapeutics Ltd's Key Ratios

Bicycle Therapeutics Ltd has a market cap of $676.90 million, indicating a price to book ratio of 3.1395 and a price to sales ratio of 61.6912.

In the last 12-months Bicycle Therapeutics Ltd’s revenue was $14.46 million with a gross profit of $-67146000 and an EBITDA of $-112964000. The EBITDA ratio measures Bicycle Therapeutics Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Bicycle Therapeutics Ltd’s operating margin was -806.56% while its return on assets stood at -16.38% with a return of equity of -36.54%.

In Q4, Bicycle Therapeutics Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 15.5%.

Bicycle Therapeutics Ltd’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-4.22 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bicycle Therapeutics Ltd’s profitability.

Bicycle Therapeutics Ltd stock is trading at a EV to sales ratio of 39.296 and a EV to EBITDA ratio of -6.1231. Its price to sales ratio in the trailing 12-months stood at 61.6912.

Bicycle Therapeutics Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$410.61 million
Total Liabilities
$53.34 million
Operating Cash Flow
Capital Expenditure
$1.45 million
Dividend Payout Ratio

Bicycle Therapeutics Ltd ended 2023 with $410.61 million in total assets and $0 in total liabilities. Its intangible assets were valued at $410.61 million while shareholder equity stood at $270.78 million.

Bicycle Therapeutics Ltd ended 2023 with $0 in deferred long-term liabilities, $53.34 million in other current liabilities, 387000.00 in common stock, $-331096000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $339.15 million and cash and short-term investments were $339.15 million. The company’s total short-term debt was $3,125,000 while long-term debt stood at $30.32 million.

Bicycle Therapeutics Ltd’s total current assets stands at $369.38 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $21.21 million compared to accounts payable of $6.47 million and inventory worth $0.

In 2023, Bicycle Therapeutics Ltd's operating cash flow was $0 while its capital expenditure stood at $1.45 million.

Comparatively, Bicycle Therapeutics Ltd paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Bicycle Therapeutics Ltd stock is currently trading at $21.27 per share. It touched a 52-week high of $50.47 and a 52-week low of $50.47. Analysts tracking the stock have a 12-month average target price of $52.21.

Its 50-day moving average was $24.12 and 200-day moving average was $24.7 The short ratio stood at 8.52 indicating a short percent outstanding of 0%.

Around 986.8% of the company’s stock are held by insiders while 8933.7% are held by institutions.

Frequently Asked Questions About Bicycle Therapeutics Ltd

The stock symbol (also called stock or share ticker) of Bicycle Therapeutics Ltd is BCYC

The IPO of Bicycle Therapeutics Ltd took place on 2019-05-23

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Tesla Inc (TSLA)

Top Gainers

Last Price
Helbiz Inc (HLBZ)

Top Losers

Last Price
Imara Inc (IMRA)


Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.


Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT